|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Iain MacGilp, PhD, says the path to delivering stable, apparently simple solution, suspension, or emulsion formulations is multi-faceted and requires a constant focus on key control measures through pre-formulation development to commercialization.
|
|
|
Jim Huang, PhD, discusses the issues associated with amorphous formulations, including solid state stability, chemical stability, reproducibility of API manufacturing, impurity of API, stability in aqueous solution, in vitro in vivo performance, and process and scale-up.
|
|
|
Marc Brown, PhD, Jon Lenn, PhD, and Jeremy Drummond, PhD, believe it is essential the lead (and potentially a back-up formulation depending on any risk factors identified) has been optimized and characterized to demonstrate it will maintain its quality and performance as well as provide the best chance of measurable success in the clinical setting.
|
|
|
Sy Pretorius, MD, Senior VP, Medical & Scientific Services at PAREXEL, discusses the new Patient Innovation Center and how it is helping to improve the patient experience, enhance study recruitment and retention, reduce costs, and deliver better data.
|
|
|
|
|
|
|
|
|

ILC Dover is a world-leader in the innovative design and production of engineered flexible protective solutions, for pharmaceutical and biopharmaceutical, flood protection, personal protection, bulk packaging, and aerospace industries. Our customers will attest to our relentless dedication to high value products, advanced technology, and responsive service, as our visionary solutions have improved efficiency while safeguarding people, product, and infrastructure in hazardous conditions since 1947. Click here for more.
|
|
|
|
|
|
 |
|
ANA Therapeutics, a Silicon Valley-based biotech start-up, and Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, recently announced a partnership to support the….
|
|
 |
|
EyePoint Pharmaceuticals, Inc. and Ocumension Therapeutics recently announced the expansion of their exclusive license agreements for the development and commercialization of….
|
|
 |
|
Humanetics Corporation and Pharmaceutics International, Inc. (Pii) will work together to support a clinical trial of BIO 300 in COVID-19 patients…..
|
|
 |
|
Edinburgh-based biotech company Ingenza Ltd. has made a significant breakthrough in the race to develop and manufacture a cost-effective vaccine against SARS-CoV-2, the virus responsible for the current COVID-19 pandemic…..
|
|
|
|
|
Upcoming eNewsletter Features:
September 2 – Drug Delivery
September 9 – Injection Devices
|
|
|
|
|
|
|
|